Investigator

Mariana Concentino Menezes Brum

Pós-doutoranda · Instituto Nacional do Câncer, Programa de Terapia Celular e Gênica

About

MCMMariana Concentin…
Papers(1)
Osteopontin-c gene ex…
Collaborators(7)
Alessandra SerainAnnie Cristhine Morae…ERP GimbaG Nestal de MoraesLuciana Bueno FerreiraLuciana da Torre Carn…Mariana Boroni
Institutions(4)
Instituto Nacional De…Universidade Federal …Brazilian National Ca…Universidade Federal …

Papers

Osteopontin-c gene expression and subcellular localization in ovarian cancer cells: Implications for prognosis and therapeutic responses

Background Osteopontin is a glycophosphoprotein aberrantly expressed in several tumor types, which exhibits several isoforms generated by post-translational and post-transcriptional mechanisms, including alternative splicing. Among total osteopontin (tOPN), the osteopontin-c (OPN-c) splice variant has been the most explored with an oncogenic role described for a range of tumor types. Especially in ovarian cancer (OC) cells, OPN-c is found overexpressed, presenting both diagnostic and prognostic implications. Objective In this review article, we aim to outline OPN-c roles in cancer, particularly in OC, in which it has been reported as a diagnostic biomarker. Methods We used PubMed search, and experimental procedures were summarized at the Figure legends. Results We identified cytoplasmic, perinuclear, and nuclear OPN-c in OC cells that overexpress this OPN splice variant. Moreover, we report that OPN-c splicing isoform is found highly expressed in endometrioid OC patients’ samples, compared to non-neoplastic ovarian tissues. Also, OPN-c expression levels have been associated with worse overall survival and worse progression-free survival in patients with both endometrioid and serous OC. Furthermore, OPN-c may be involved in a wide range of tumor features evoked by signaling pathways, such as AKT, ERK, and FAK. Conclusions Therefore, a better comprehension of OPN-c roles in OC can further contribute to its application as a biomarker as well as a target for putative treatment strategies, especially those aiming to sensitize tumor cells to chemotherapeutic agents currently used in the OC treatment.

6Works
1Papers
7Collaborators
Ovarian NeoplasmsPrognosisBiomarkers, TumorNeoplasm ProteinsNeoplasms

Positions

2025–

Pós-doutoranda

Instituto Nacional do Câncer · Programa de Terapia Celular e Gênica

Education

Biomédica

Mariana CM Brum · Laureate International Universities IBMR

2026

Pós-doutoranda

Instituto Nacional de Câncer (INCA)

2024

Doutora em Oncologia

Instituto Nacional do Câncer · Programa de Hemato-Oncologia Molecular e Celular

2018

Mestre em Oncologia

Instituto Nacional de Câncer (INCA)

Country

BR